Q1 fall in number of trials in Russia a ‘blip,’ says Synergy Research

By Gareth Macdonald

- Last updated on GMT

Related tags: Clinical trial

The fall in the number of trials conducted in Russia in Q1 is a ‘temporary blip’ says Synergy Research Group general manager Igor Stefanov, who cites recent changes to the approval process, rather than a drop in demand, as the key factor.

The comment follows the publication of the English language version of Synergy’s ‘Orange Paper​,’ which showed that 95 trials were initiated in the first quarter, down 29 per cent on the number started during the equivalent period in 2010.

Synergy, a Moscow-based contract research organisation (CRO), attributed much of the decline the fact that fewer multinational, multi-center research programmes had included a Russian site during the period compared with Q1 last year.

Additionally, the number of studies conducted solely in Russia was also down, falling 50 per cent to 18. There were seven fewer Phase I trial, 11 less Phase II and 10 per cent less Phase III programmes.

Regulatory revisions

However, the decline is not indicative of a lack of demand according to Stefanov, who told Outsoutcing-pharma.com that: “I would regard this reduction as a temporary blip, rather than a trend.

Instead he linked the drop to changes to Russia’s laws, which saw responsibility for approval trials change from one regulatory authority, the Roszrdarnadzor, to the Ministry of Health and Social Development (MoH)

Such a transfer is quite a painful process, and it seriously affected the approval process…the number of studies approved in September-October last year was zero.

The demand for [clinical research in] Russia is still high, and once the approval process is back on track, we'll be definitely enjoying the long term trend of growth in the number of trials that we saw in 2000-2009.

Stefanov also suggested that recent changes to Russia's “Circulation of Medicines" laws, which made conducting trials in the country a mandatory requirement for product approval, would aid recovery.

This contention echoes the conclusions of recent analysis by GBI Research, which cited the new law as one of the factors that would drive the value of the Russian trial sector to around $309m by 2017.

Related news

Show more

Related products

show more

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

What the Best Clinical Study Build Pros Do

What the Best Clinical Study Build Pros Do

Formedix | 09-May-2022 | Technical / White Paper

Getting your clinical study designed and built ready for data collection takes A LOT of work and expertise… you've got to do all your CRF designs;...

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 18-Apr-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us


View more